News|Videos|November 5, 2025

The Importance of Data Strategy and Infrastructure in AI's Potential

Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI’s full potential in pharma.

Pharmaceutical Executive: How important is data strategy and infrastructure in realizing the full potential of AI in pharma, and what best practices have you seen for ensuring AI-driven insights are accurate and actionable?
Raj Indupuri: Yeah, so that's an excellent question, and that's in terms of data infrastructure. That's kind of foundation without data, there is no AI, right? So to bring these AI capabilities that users can trust. In terms of adoption or scale, it has to start with strong data foundations. So that's another differentiator that we have as a company, because we start as a data company, we build infrastructure so that we can bring all this patient data together, and then we can embed this intelligence on governed data, right? So having those controls, those guardrails, the safety practices around our own data, right, is incredibly important if you want to benefit from the use and adoption of AI and also the performance of these models, right? So the Tech has evolved so much that it's with prompts you can build this intelligence now, so you don't need to be a data scientist anymore, right? That's good and the bad, right? So the bar to build AI capabilities have reduced significantly that on the other side right for us to build responsible AI. So you got to ensure that there are a lot of guardrails. So going back to your question, strong data foundations is an imperative if you want to have any chance to have success with AI.


Related to this article

Dr. Bo Liang
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.